Cited by 152Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalus

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

Open access

Welge, Volker, Fiege, Oliver, Lewczuk, Piotr, Mollenhauer, Brit, Esselmann, Hermann, Klafki, Hans-Wolfgang, Wolf, Stefanie, Trenkwalder, Claudia, Otto, Markus, Kornhuber, Johannes, Wiltfang, Jens, Bibl, Mirko·2009·Journal of Neural Transmission

DOI 10.1007/s00702-008-0177-6

Open this paper in CoChat — free account

Abstract

Cerebrospinal fluid (CSF) concentrations of amyloid-beta (Abeta) 1-38, 1-40, 1-42, total-tau and phospho-tau in samples from 156 patients with Alzheimer's disease (AD) (n = 44), depressive cognitive complainers (DCC, n = 25) and various other forms of non-Alzheimer dementias (NAD, n = 87) were analyzed by electrochemiluminescence and enzyme linked immunosorbent assay, respectively. A significant decrease of CSF Abeta1-42 was the most powerful single marker for differentiation of AD from DCC, yielding accuracies of beyond 85%. Increased p-tau and the ratio Abeta1-42/Abeta1-38 yielded accuracies of beyond 80 and 85%, respectively, to discriminate AD versus NAD. Combining p-tau with Abeta1-42/Abeta1-38 resulted in a sensitivity of 94% for detection of AD and 85% specificity for excluding NAD. Decreased CSF Abeta1-42 represents a core biomarker for AD. The lack of specificity for exclusion of NAD can be most effectively compensated by the ratio Abeta1-42/Abeta1-38. The ratio Abeta1-42/Abeta1-38/p-tau powerfully discriminates AD versus NAD and fulfils the accuracy requirements for an applicable screening and differential diagnostic AD biomarker.

Integrity signals

Registry

Crossref · 10.1007/s00702-008-0177-6

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Vascular dementia: Diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop*
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Primary Progressive Aphasia
Weıntraub, S. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120075013 · Cited by 3,018
DECLARATION OF HELSINKI.
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 1×
“The major constituent of NFT’s is tau, a microtubule-associated protein that undergoes excessive phosphorylation (phosphorylated tau, p-tau) at multiple sites (e.g. p-tau199, p-tau181 and p-tau231) and aggregates into paired helical filaments in AD (Lee et al. 1991).”
Background
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 2×
“…distributions of different Ab species are regulated within very narrow limits (Wiltfang et al. 2002; Bibl et al. 2007a; Wiltfang et al. 2007) (4) Distinct g-secretase activities may be reflected most adequately by the ratio Ab1-42/Ab1-40 Wiltfang et al. 2001) or Ab1-38/Ab1-40 (Weggen et al. 2001).”
Background

Show all 42 references

Sorted by citations

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Alzheimer's disease
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
Total and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B. A., Jeng, A. T., Skorupa, T., Carrell, D., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.026 · Cited by 383
Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease
Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353
Truncated and modified amyloid-beta species
Kummer, M. P., & Heneka, M. T. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt258 · Cited by 351
Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease
Mulder, C., Verwey, N. A., van der Flier, W. M., Bouwman, F. H., Kok, A., van Elk, E. J., Scheltens, P., & Blankenstein, M. A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.130518 · Cited by 339
Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253
MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid
Müller, M., Kuiperij, H. B., Claassen, J. A., Küsters, B., & Verbeek, M. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.07.005 · Cited by 205
Conformations and Biological Activities of Amyloid Beta Peptide 25-35
Millucci, L., Ghezzi, L., Bernardini, G., & Santucci, A. (2010) · Current Protein and Peptide Science · doi:10.2174/138920310790274626 · Cited by 197
Diagnostic and therapeutic potential of exosomes in Alzheimer’s disease
Martins, T. S., Trindade, D., Vaz, M., Campelo, I., Almeida, M., Trigo, G., Silva, O. A. B. D. C. E., & Henriques, A. G. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15112 · Cited by 177
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B. G., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 162
Self-citation
Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P
Koopman, K., Bastard, N. L., Martin, J., Nagels, G., Deyn, P. P. D., & Engelborghs, S. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.02.017 · Cited by 153
Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers
Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 147
Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020
Hampel, H. J., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C. J., Bakardjian, H., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.009 · Cited by 148
Alzheimer’s Retinopathy: Seeing Disease in the Eyes
Mirzaei, N., Shi, H., Oviatt, M., Doustar, J., Rentsendorj, A., Fuchs, D.-T. S., Sheyn, J., Black, K. L., Koronyo, Y., & Koronyo‐Hamaoui, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00921 · Cited by 136
Genetic architecture of Alzheimer's disease
Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126
“…levels of CSF Aβ42 and high levels of total tau or phosphorylated tau (particularly p-tau181) capable of differentiating AD from mild cognitive impairment and other dementias such as frontotemporal dementia and Lewy body dementia (Sunderland et al., 2003; Welge et al., 2009; Cruchaga et al., 2013).”
Background
The French Series of Autosomal Dominant Early Onset Alzheimer's Disease Cases: Mutation Spectrum and Cerebrospinal Fluid Biomarkers
Wallon, D., The collaborators of the GMAJ project, Rousseau, S., Rovelet‐Lecrux, A., Quillard‐Muraine, M., Guyant‐Maréchal, L., Martinaud, O., Pariente, J., Puel, M., Rollin‐Sillaire, A., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120172 · Cited by 134
CSF biomarkers for Alzheimer's disease: current utility and potential future use
Holtzman, D. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.003 · Cited by 124
Quantitation of amyloid beta peptides Aβ1–38, Aβ1–40, and Aβ1–42 in human cerebrospinal fluid by ultra-performance liquid chromatography–tandem mass spectrometry
Lame, M. E., Chambers, E. E., & Blatnik, M. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.08.010 · Cited by 129
Performance of Aβ1-40, Aβ1-42, Total Tau, and Phosphorylated Tau as Predictors of Dementia in a Cohort of Patients with Mild Cognitive Impairment
Parnetti, L., Chiasserini, D., Eusebi, P., Giannandrea, D., Bellomo, G., Carlo, C. D., Padiglioni, C., Mastrocola, S., Lisetti, V., & Calabresi, P. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111349 · Cited by 114
Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis
Struyfs, H., Broeck, B. V., Timmers, M., Fransén, E., Sleegers, K., Broeckhoven, C. V., Deyn, P. P. D., Streffer, J. R., Mercken, M. H., & Engelborghs, S. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141986 · Cited by 104
Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease
Alawode, D. O. T., Heslegrave, A., Ashton, N. J., Karikari, T. K., Simrén, J., Montoliu‐Gaya, L., Pannee, J., O’Connor, A., Weston, P. S. J., Lantero‐Rodriguez, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13332 · Cited by 107
Aggregation of Disordered Proteins Associated with Neurodegeneration
Tsoi, P. S., Quan, M. D., Ferreon, J. C., & Ferreon, A. C. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043380 · Cited by 103
Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer's disease
Jentsch, S., Schweitzer, D., Schmidtke, K., Peters, S., Dawczynski, J., Bär, K., & Hammer, M. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12609 · Cited by 96
Cerebrospinal Fluid Aβ to Tau Ratio and Postoperative Cognitive Change
Xie, Z., McAuliffe, S., Swain, C. A., Ward, S. A. P., Crosby, C. A., Zheng, H., Sherman, J. C., Dong, Y., Zhang, Y., Sunder, N., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318298b077 · Cited by 92
Investigation of the Molecular Role of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease
Girotra, P., Behl, T., Sehgal, A., Singh, S., & BUNGAU, S. G. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01824-8 · Cited by 92
Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall
Mattsson, N., Blennow, K., & Zetterberg, H. (2010) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.131 · Cited by 86
Particulate Matter Exposure Exacerbates Amyloid-β Plaque Deposition and Gliosis in APP/PS1 Mice
Sahu, B., Mackos, A. R., Floden, A. M., Wold, L. E., & Combs, C. K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200919 · Cited by 92
Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers
Lewczuk, P., Zimmermann, R., Wiltfang, J., & Kornhuber, J. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0277-y · Cited by 86
Self-citation
Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
Fagan, A. M., & Holtzman, D. M. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.83 · Cited by 88
An Insight into Cellular and Molecular Mechanisms Underlying the Pathogenesis of Neurodegeneration in Alzheimer’s Disease
Ratan, Y., Rajput, A., Maleysm, S., Pareek, A., Jain, V. K., Pareek, A., Kaur, R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051398 · Cited by 89
Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid
Gabelle, A., Roche, S., Gény, C., Bennys, K., Labauge, P. M., Tholance, Y., Quadrio, I., Tiers, L., Gor, B., Chaulet, C., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.08.022 · Cited by 80
Alzheimer’s Disease: A Clinical Practice-Oriented Review
Alves, L., Correia, A. S., Miguel, R., Alegria, P., & Bugalho, P. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00063 · Cited by 74
Single-step immunoassays and microfluidic droplet operation: Towards a versatile approach for detection of amyloid-β peptide-based biomarkers of Alzheimer’s disease
Mai, T. D., Ferraro, D., Aboud, N., Renault, R., Serra, M., Tran, N. T., Viovy, J., Smadja, C., Descroix, S., & Taverna, M. (2017) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2017.09.003 · Cited by 68
Biomarkers in translational research of Alzheimer’s Disease
Tarawneh, R., & Holtzman, D. M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.04.006 · Cited by 67
Decreased sAβPPβ, Aβ 38 , and Aβ 40 Cerebrospinal Fluid Levels in Frontotemporal Dementia
Gabelle, A., Roche, S., Gény, C., Bennys, K., Labauge, P. M., Tholance, Y., Quadrio, I., Tiers, L., Gor, B., Boulanghien, J., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110515 · Cited by 67
The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-ε4 Carriers
Benítez, B. A., Karch, C. M. M., Cai, Y., Jin, S. C., Cooper, B., Carrell, D., Bertelsen, S. E., Chibnik, L. B., Schneider, J. A., Bennett, D., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003685 · Cited by 68
Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00696-1 · Cited by 62
Serum IL‐8 is a marker of white‐matter hyperintensities in patients with Alzheimer's disease
Zhu, Y., Chai, Y. L., Hilal, S., Ikram, M. K., Venketasubramanian, N., Wong, B., Chen, C., & Lai, M. K. P. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.001 · Cited by 61
Diffusion Kurtosis Imaging: A Possible MRI Biomarker for AD Diagnosis?
Struyfs, H., Hecke, W. V., Veraart, J., Sijbers, J., Slaets, S., Belder, M. D., Wuyts, L. L., Peters, B., Sleegers, K., Robberecht, C., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150253 · Cited by 61
Neuroimaging and Biochemical Markers in the Three Variants of Primary Progressive Aphasia
Gil‐Navarro, S., Lladó, A., Rami, L., Castellvı́, M., Bosch, B., Bargalló, N., Lomeña, F., Reñé, R., Montagut, N., Antonell, A., et al. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000346289 · Cited by 60
Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
Bibl, M., Gallus, M., Welge, V., Esselmann, H., Wolf, S., Rüther, E., & Wiltfang, J. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0801-3 · Cited by 65
Self-citation
Evaluation of the Cerebrospinal Fluid Amyloid-β1-42/Amyloid-β1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders
Nutu, M., Zetterberg, H., Londos, E., Minthon, L., Nägga, K., Blennow, K., Hansson, O., & Öhrfelt, A. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000353442 · Cited by 57
Dissecting IWG-2 typical and atypical Alzheimer’s disease: insights from cerebrospinal fluid analysis
Paterson, R. W., Toombs, J., Slattery, C. F., Nicholas, J. M., Andréasson, U., Magdalinou, N. K., Blennow, K., Warren, J. D., Mummery, C. J., Rossor, M. N., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7904-3 · Cited by 57
CSF amyloid 38 as a novel diagnostic marker for dementia with Lewy bodies
Mulugeta, E., Londos, E., Ballard, C., Alves, G., Zetterberg, H., Blennow, K., Skogseth, R., Minthon, L., & Aarsland, D. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199398 · Cited by 54
Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study
Hilal, S., Wolters, F. J., Verbeek, M. M., Vanderstichele, H., Ikram, M. K., Stoops, E., Ikram, M. A., & Vernooij, M. W. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0395-6 · Cited by 55
Clinical significance of fluid biomarkers in Alzheimer’s Disease
Lewczuk, P., Łukaszewicz‐Zając, M., Mroczko, P., & Kornhuber, J. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00107-0 · Cited by 56
Self-citation
The Aβ(1–38) peptide is a negative regulator of the Aβ(1–42) peptide implicated in Alzheimer disease progression
Quartey, M. O., Nyarko, J. N. K., Maley, J. M., Barnes, J. R., Bolanos, M. A. C., Heistad, R. M., Knudsen, K. J., Pennington, P. R., Buttigieg, J. A., de Carvalho, C. E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80164-w · Cited by 54
Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis
Struyfs, H., Niemantsverdriet, E., Goossens, J., Fransén, E., Martin, J., Deyn, P. P. D., & Engelborghs, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00138 · Cited by 53
Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: Change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau
Ray, B., Reyes, P. F., & Lahiri, D. K. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.07.011 · Cited by 52
Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease
Adamczuk, K., Schaeverbeke, J. M., Vanderstichele, H., Lilja, J., Nelissen, N., Laere, K. V., Dupont, P. J., Hilven, K., Poesen, K., & Vandenberghe, R. R. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0159-5 · Cited by 49
Novel Exosome Biomarker Candidates for Alzheimer’s Disease Unravelled Through Mass Spectrometry Analysis
Martins, T. S., Marçalo, R., Silva, C. B. D. C. E., Trindade, D., Catita, J. A. M., Amado, F. M. L., Melo, T., Rosa, I. M., Vogelgsang, J. S., Wiltfang, J., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02762-1 · Cited by 46
Self-citation
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
Leko, M. B., Štrac, D. Š., Mück‐Šeler, D., Pivac, N., Stanić, G., Hof, P. R., & Šimić, G. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.347 · Cited by 48
Alzheimer CSF biomarkers in routine clinical setting
Tabaraud, F., Leman, J. P., Milor, A.-M., Roussie, J. M., Barrière, G., Tartary, M., Boutros-Toni, F., & Rigaud, M. (2011) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2011.01592.x · Cited by 44
A New Version of Grain-128 with Authentication
Ågren, M., Hell, M., Johansson, T., & Meier, W. (2011) · Lund University Publications (Lund University) · Cited by 43
Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
Alawode, D. O. T., Fox, N. C., Zetterberg, H., & Heslegrave, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.837390 · Cited by 41
Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment
Sierra, A., Balasa, M., Olives, J., Antonell, A., Iranzo, Á., Castellvı́, M., Bosch, B., Grau‐Rivera, O., Fernández‐Villullas, G., Rami, L., et al. (2015) · Neurodegenerative Diseases · doi:10.1159/000439258 · Cited by 42
Performance Evaluation of an Automated ELISA System for Alzheimer’s Disease Detection in Clinical Routine
Chiasserini, D., Biscetti, L., Farotti, L., Eusebi, P., Salvadori, N., Lisetti, V., Baschieri, F., Chipi, E., Frattini, G., Stoops, E., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160298 · Cited by 40
Potential of FTIR Spectroscopy Applied to Exosomes for Alzheimer’s Disease Discrimination: A Pilot Study
Martins, T. S., Magalhães, S., Rosa, I. M., Vogelgsang, J. S., Wiltfang, J., Delgadillo, I., Catita, J. A. M., Silva, O. A. B. D. C. E., Nunes, A., & Henriques, A. G. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191034 · Cited by 41
Self-citation
APP mutations in the Aβ coding region are associated with abundant cerebral deposition of Aβ38
Moro, M. L., Giaccone, G., Lombardi, R., Indaco, A., Uggetti, A., Morbin, M., Saccucci, S., Fede, G. D., Catania, M., Walsh, D. M., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1061-x · Cited by 39
Usefulness of Biomarkers in the Diagnosis and Prognosis of Early-Onset Cognitive Impairment
Balasa, M., Sánchez‐Valle, R., Antonell, A., Bosch, B., Olives, J., Rami, L., Castellvı́, M., Molinuevo, J. L., & Lladó, A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132195 · Cited by 39
Molecular Diagnostics of Calcineurin-Related Pathologies
Musson, R. E. A., Cobbaert, C. M., & Smit, N. P. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.167296 · Cited by 37
Magneto-immunocapture with on-bead fluorescent labeling of amyloid-β peptides: towards a microfluidized-bed-based operation
Mai, T. D., Pereiro, I., Hiraoui, M., Viovy, J., Descroix, S., Taverna, M., & Smadja, C. (2015) · The Analyst · doi:10.1039/c5an01179e · Cited by 36
Depressive disorders in the elderly and dementia: An update
Dias, N. S., Barbosa, I. G., Kuang, W., & Teixeira, A. L. (2020) · Dementia & Neuropsychologia · doi:10.1590/1980-57642020dn14-010001 · Cited by 34
Aβ38 in the Brains of Patients with Sporadic and Familial Alzheimer's Disease and Transgenic Mouse Models
Reinert, J., Martens, H., Hüttenrauch, M., Kolbow, T., Lannfelt, L., Ingelsson, M., Paetau, A. E., Verkkoniemi‐Ahola, A., Bayer, T. A., & Wirths, O. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131373 · Cited by 33
Biomarkers of Alzheimer’s disease in severe obstructive sleep apnea–hypopnea syndrome in the Chinese population
Kong, W., Zheng, Y., Xu, W., Gu, H., & Wu, J. (2020) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-020-05948-2 · Cited by 31
Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review
Chaudhry, A., Houlden, H., & Rizig, M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116886 · Cited by 33
Amyloid-β as a biomarker for Alzheimer’s disease: quantification methods in body fluids
Galozzi, S., Marcus, K., & Barkovits, K. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1065183 · Cited by 30
Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond
Grasso, G. (2018) · Mass Spectrometry Reviews · doi:10.1002/mas.21566 · Cited by 31
Tau in Late-Life Depression: A Systematic Review and Meta-Analysis
Brown, E. E., Iwata, Y., Chung, J. K., Gerretsen, P., & Graff-Guerrero, A. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160401 · Cited by 29
Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer’s disease and other neurodegenerative dementias
Genius, J., Klafki, H., Benninghoff, J., Esselmann, H., & Wiltfang, J. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0362-3 · Cited by 29
Self-citation
Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
Park, S. A., Chae, W. S., Kim, H. J., Shin, H. S., Kim, S., Im, J. Y., Ahn, S. I., Min, K. D., Yim, S. J., Ye, B. S., et al. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000184 · Cited by 28
DW14006 as a direct AMPKα1 activator improves pathology of AD model mice by regulating microglial phagocytosis and neuroinflammation
Lv, J., Wang, W., Zhu, X., Xu, X., Yan, Q., Lu, J., Shi, X., Wang, Z., Zhou, J., Huang, X., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.07.041 · Cited by 28
The Potential Roles of Exosomes Carrying APP and Tau Cleavage Products in Alzheimer’s Disease
Zhao, Y., Gu, Y., Zhang, Q., Liu, H., & Liu, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051883 · Cited by 29
Patchouli alcohol as a selective estrogen receptor β agonist ameliorates AD-like pathology of APP/PS1 model mice
Yan, Q., Lv, J., Shen, X., Yang, J., Yang, J.-Z., Nie, R.-F., Lu, J., Huang, Y.-J., Wang, J.-Y., & Shen, X. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00857-4 · Cited by 24
Sex Differences in Apolipoprotein E and Alzheimer Disease Pathology Across Ancestries
Xu, X., Kwon, J., Yan, R., Apio, C., Song, S. C., Heo, G., Yang, Q., Timsina, J., Liu, M., Budde, J., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.0562 · Cited by 30
cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases
Spitzer, P., Klafki, H., Blennow, K., Buée, L., Esselmann, H., Herukka, S., Jiménez, C. R., Klivènyi, P., Lewczuk, P., Maler, J. M., et al. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/548145 · Cited by 25
Self-citation
Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment and Dementia
Sonnen, J. A., Montine, K. S., Quinn, J. F., Breitner, J. C. S., & Montine, T. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1236 · Cited by 24
Clinical phenotypes and genetic biomarkers of FTLD
Galimberti, D., & Scarpini, E. A. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0804-0 · Cited by 23
sPDGFRβ and neuroinflammation are associated with AD biomarkers and differ by race: The ASCEND Study
Butts, B., Huang, H., Hu, W. T., Kehoe, P. G., Miners, J. S., Verble, D. D., Zetterberg, H., Zhao, L., Trotti, L. M., Benameur, K., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13457 · Cited by 20
The "Alzheimer's disease signature": potential perspectives for novel biomarkers
Davinelli, S., Intrieri, M., Russo, C., Costanzo, A. D., Zella, D., Bosco, P., & Scapagnini, G. (2011) · Immunity & Ageing · doi:10.1186/1742-4933-8-7 · Cited by 22
Exosomal Aβ-Binding Proteins Identified by “In Silico” Analysis Represent Putative Blood-Derived Biomarker Candidates for Alzheimer´s Disease
Martins, T. S., Marçalo, R., Ferreira, M., Vaz, M., Silva, R. M., Rosa, I. M., Vogelgsang, J. S., Wiltfang, J., Silva, O. A. B. D. C. E., & Henriques, A. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083933 · Cited by 21
Self-citation
Correlation between Cognitive Impairment and Peripheral Biomarkers - Significance of Phosphorylated Tau and Amyloid-β in Alzheimer’s Disease: A New Insight
Sarkar, S., Bhui, U., Kumar, B., Ashique, S., Kumar, P., Sharma, H., Bhowmick, M., Pal, R., & Kumar, T. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822329981241007105405 · Cited by 25
Neurochemical biomarkers in Alzheimer’s disease and related disorders
Bibl, M., Esselmann, H., & Wiltfang, J. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612455367 · Cited by 22
Self-citation
Phenotype and imaging features associated with APP duplications
Grangeon, L., Charbonnier, C., Zaréa, A., Rousseau, S., Rovelet‐Lecrux, A., Bendetowicz, D., Lemaitre, M., Malrain, C., Quillard‐Muraine, M., Cassinari, K., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01172-2 · Cited by 18
A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
Park, S. A., Kang, J.-H., Kang, E., Ki, C., Roh, J. H., Youn, Y. C., Kim, S. Y., & Kim, S. (2015) · Journal of Clinical Neurology · doi:10.3988/jcn.2015.11.2.132 · Cited by 19
Further evidence about the crucial role of CSF biomarkers in diagnosis of posterior cortical atrophy
Coppi, E., Ferrari, L., Santangelo, R., Caso, F., Pinto, P., Passerini, G., Comi, G., & Magnani, G. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1644-5 · Cited by 22
Decreased striatal dopamine transporter uptake in the non‐fluent/agrammatic variant of primary progressive aphasia
Gil-Navarro, S., Lomeña, F., Cot, A., Lladó, A., Montagut, N., Castellví, M., Bosch, B., Rami, L., Antonell, A., Balasa, M., et al. (2013) · European Journal of Neurology · doi:10.1111/ene.12196 · Cited by 17
Alzheimer’s disease basics: we all should know
Das, S. K. (2025) · Neurological Research · doi:10.1080/01616412.2025.2529560 · Cited by 19
Extracellular Vesicle-Enriched miRNA-Biomarkers Show Improved Utility for Detecting Alzheimer’s Disease Dementia and Medial Temporal Atrophy
Chai, Y. L., Strohm, L., Zhu, Y., Chia, R. S. L., Chong, J. R., Suresh, D. D., Zhou, L. H., Too, H., Hilal, S., Radivoyevitch, T., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230572 · Cited by 19
Neutral polymers as coatings for high resolution electrophoretic separation of Aβ peptides on glass microchips
Mesbah, K., Verpillot, R., Chiari, M., Pallandre, A., & Taverna, M. (2014) · The Analyst · doi:10.1039/c4an01296h · Cited by 17
Tau Protein Alterations Induced by Hypobaric Hypoxia Exposure
Pena, E., Martin-Salamanca, R. S., Alam, S. E., Flores, K., & Arriaza, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020889 · Cited by 16
Biomarker bei Demenzen und anderen neurodegenerativen Erkrankungen
Wiltfang, J., Lewczuk, P., & Otto, M. (2016) · Der Nervenarzt · doi:10.1007/s00115-016-0238-2 · Cited by 15
Self-citation
The contributions of metabolomics in the discovery of new therapeutic targets in Alzheimer's disease
Samey, R. A., Antier, D., Mavel, S., Dufour‐Rainfray, D., Balageas, A., Beaufils, É., Emond, P., Foucault‐Fruchard, L., & Chalon, S. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12654 · Cited by 16
A systematic review of amyloid-β peptides as putative mediators of the association between affective disorders and Alzheimer׳s disease
Abbasowa, L., & Heegaard, N. H. H. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.050 · Cited by 15
FTIR Spectroscopy and Blood-Derived Extracellular Vesicles Duo in Alzheimer’s Disease
Martins, T. S., Ferreira, M., Magalhães, S., Leandro, K., de Almeida, L. P., Vogelgsang, J. S., Breitling, B., Hansen, N., Esselmann, H., Wiltfang, J., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231239 · Cited by 18
Self-citation
Imaging and biomarkers for Alzheimer's disease
Allan, C. L., Sexton, C. E., Welchew, D., & Ebmeier, K. P. (2010) · Maturitas · doi:10.1016/j.maturitas.2009.12.006 · Cited by 15
Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology
Povala, G., Bellaver, B., Bastiani, M. A. D., Brum, W. S., Ferreira, P. C. L., Bieger, A., Pascoal, T. A., Benedet, A. L., Souza, D. O., Araújo, R., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00712-3 · Cited by 14

Authors: Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., Wiltfang, J., & Bibl, M.
Affiliations: University of Duisburg-Essen (DE)
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
University of Göttingen (DE)
Paracelsus Elena Klinik Kassel (DE)
Universität Ulm (DE)
Corresponding author: Bibl, Mirko
ORCID: Lewczuk, Piotr
Mollenhauer, Brit
Esselmann, Hermann
Klafki, Hans-Wolfgang
Trenkwalder, Claudia
Otto, Markus
Kornhuber, Johannes
Wiltfang, Jens
Venue: Journal of Neural Transmission
Publisher: Springer Science and Business Media LLC
Published: 2009-01-14
Volume: 116
Issue: 2
Pages: 203-212
ISSN: 0300-9564 (ISSN-L)
1435-1463
DOI: 10.1007/s00702-008-0177-6
OpenAlex: W2041245991
Cited by: 152
References: 42
Citations by year: 2026: 2 · 2025: 5 · 2024: 10 · 2023: 7 · 2022: 6 · 2021: 10 · 2020: 17 · 2019: 2 · 2018: 3 · 2017: 8 · 2016: 5 · 2015: 13 · 2014: 14 · 2013: 13 · 2012: 10
FWCI: 7.63
Type: journal article
Language: en
Open access: green
resolver.sub.uni-goettingen.de
Licence: cc-by
www.springer.com/tdm (tdm)
Locations: Journal of Neural Transmission (publishedVersion)
PubMed (publishedVersion)
GRO (submittedVersion, cc-by)
Funders: Baden-Württemberg Stiftung
Bundesministerium für Bildung und Forschung
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords: Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, phosphorylated tau, total tau, differential diagnosis of dementia, non-Alzheimer's dementia, diagnostic accuracy, screening biomarkers
MeSH terms: Aged, Alzheimer Disease, Enzyme-Linked Immunosorbent Assay, Female, Humans, Luminescent Measurements, Male, Middle Aged, Phosphorylation, ROC Curve, Biomarkers, Amyloid beta-Peptides, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks